FY2025 EPS Estimates for Maze Therapeutics Raised by Wedbush

Key Points

• Wedbush analysts have revised their FY2025 earnings estimate for Maze Therapeutics to ($3.37) per share, slightly improving from the previous forecast of ($3.39), maintaining an "Outperform" rating with a $17.00 target price.
• Maze Therapeutics reported a quarterly EPS of ($0.77), exceeding the consensus estimate of ($0.79) by $0.02, indicating better-than-expected performance.
• Investment firms are showing strong interest, with several analysts rating the stock as "buy," including a recent initiation by HC Wainwright at a $34.00 target price.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities research analysts at Wedbush upped their FY2025 EPS estimates for shares of Maze Therapeutics in a research report issued on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($3.37) per share for the year, up from their prior estimate of ($3.39). Wedbush has a "Outperform" rating and a $17.00 price objective on the stock. Wedbush also issued estimates for Maze Therapeutics' Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.70) EPS and FY2029 earnings at ($2.83) EPS.

Other equities analysts have also recently issued reports about the stock. HC Wainwright started coverage on shares of Maze Therapeutics in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price objective for the company. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $25.60.

Maze Therapeutics Stock Up 0.2%

Shares of NASDAQ:MAZE traded up $0.03 on Friday, reaching $13.48. The company's stock had a trading volume of 476,446 shares, compared to its average volume of 201,731. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $19.19. The business has a 50-day moving average price of $13.95.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MAZE. General Catalyst Group Management LLC bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $11,405,000. Bessemer Group Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $5,305,000. Bank of New York Mellon Corp bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $190,000. New York State Common Retirement Fund bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $25,000. Finally, Alphabet Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.